Enveric Biosciences says preclinical GloSensor assay supports non-hallucinogenic profile for EB-003
ENVB•Preclinical assay data support EB-003 profile
Enveric Biosciences reported new preclinical data supporting a non-hallucinogenic profile for lead neuroplastogenic candidate EB-003.
- A GloSensor cAMP assay showed EB-003 in a non-hallucinogenic signaling range versus reference compounds, consistent with reported 5-HT2A Gi markers.
- Results aligned with previously disclosed BRET assay findings, strengthening cross-platform evidence ahead of planned Phase 1 first-in-human development.
- The company positioned a non-hallucinogenic profile as a potential path to more conventional blinded trials and simpler outpatient use if replicated in humans.
